Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRASG12C and ARS compounds

被引:22
|
作者
Khrenova, Maria G. [1 ,2 ]
Kulakova, Anna M. [1 ]
Nemukhin, Alexander, V [1 ,3 ]
机构
[1] Lomonosov Moscow State Univ, Dept Chem, Moscow 119991, Russia
[2] Russian Acad Sci, Res Ctr Biotechnol, Bach Inst Biochem, Moscow 119071, Russia
[3] Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow 119334, Russia
基金
俄罗斯科学基金会;
关键词
FORCE-FIELD; CRYSTAL-STRUCTURE; ACTIVE-SITE; RAS; MOLECULES; SOLVATION; MUTANT; MECHANISM; ENERGIES; COMPLEX;
D O I
10.1039/d0ob00071j
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The use of selective covalent inhibitors with low binding affinity and high reactivity with the target enzyme is a promising way to solve a long-standing problem of the "undruggable" RAS-like proteins. Specifically, compounds of the ARS family that prevent the activation of the GDP-bound G12C mutant of Kirsten RAS (KRAS) are in the focus of recent experimental research. We report the first computational characterization of the entire reaction mechanism of the covalent binding of ARS-853 to the KRAS(G12C)center dot GDP complex. The application of molecular dynamics, molecular docking and quantum mechanics/molecular mechanics approaches allowed us to model the inhibitor binding to the protein and the chemical reaction of ARS-853 with Cys12 in the enzyme binding site. We estimated a full set of kinetic constants and carried out numerical kinetic analysis of the process. Thus, we were able to compare directly the physicochemical parameters of the reaction obtained in silico and the macroscopic parameters observed in experimental studies. From our computational results, we explain the observed unusual dependence of the rate constant of covalent complex formation, k(obs), on the ARS concentration. The latter depends both on the non-covalent binding step with the equilibrium constant, Ki, and on the rate constant of covalent adduct formation, k(inact). The calculated ratio k(inact)/K-i = 213 M-1 s(-1) reproduces the corresponding experimental value of 250 +/- 30 M-1 s(-1) for the interaction of ARS-853 with KRAS(G12C). Electron density analysis in the reactive region demonstrates that covalent bond formation occurs efficiently according to the Michael addition mechanism, which assumes the activation of the CvC bond of ARS-853 by a water molecule and Lys16 in the binding site of KRAS(G12C). We also refine the k(inact) and K-i constants of the ARS-107 compound, which shares common features with ARS-853, and show that the decrease in the k(inact)/K-i ratio in the case of ARS-107 is explained by changes in both K-i and k(inact) constants.
引用
收藏
页码:3069 / 3081
页数:13
相关论文
共 25 条
  • [21] Revealing the mechanism of action of a fi rst-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31 P NMR
    Sharma, Alok K.
    Pei, Jun
    Yang, Yue
    Dyba, Marcin
    Smith, Brian
    Rabara, Dana
    Larsen, Erik K.
    Lightstone, Felice C.
    Esposito, Dominic
    Stephen, Andrew G.
    Wang, Bin
    Beltran, Pedro J.
    Wallace, Eli
    Nissley, Dwight V.
    McCormick, Frank
    Maciag, Anna E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (02)
  • [22] Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c
    Loos, Nancy H. C.
    Retmana, Irene A.
    Rijmers, Jamie
    Wang, Yaogeng
    Gan, Changpei
    Lebre, Maria C.
    Sparidans, Rolf W.
    Beijnen, Jos H.
    Schinkel, Alfred H.
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166
  • [23] Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
    Maciag, Anna E.
    Stice, James P.
    Wang, Bin
    Sharma, Alok K.
    Chan, Albert H.
    Lin, Ken
    Singh, Devansh
    Dyba, Marcin
    Yang, Yue
    Setoodeh, Saman
    Smith, Brian P.
    Ju, Jin Hyun
    Jeknic, Stevan
    Rabara, Dana
    Zhang, Zuhui
    Larsen, Erik K.
    Esposito, Dominic
    Denson, John-Paul
    Ranieri, Michela
    Meynardie, Mary
    Mehdizadeh, Sadaf
    Alexander, Patrick A.
    Abreu Blanco, Maria
    Turner, David M.
    Xu, Rui
    Lightstone, Felice C.
    Wong, Kwok-Kin
    Stephen, Andrew G.
    Wang, Keshi
    Simanshu, Dhirendra K.
    Sinkevicius, Kerstin W.
    Nissley, Dwight V.
    Wallace, Eli
    Mccormick, Frank
    Beltran, Pedro J.
    CANCER DISCOVERY, 2025, 15 (03) : 578 - 594
  • [24] ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure
    Rijmers, Jamie
    Retmana, Irene A.
    Bui, Viet
    Arguedas, Davinia
    Lebre, Maria C.
    Sparidans, Rolf W.
    Beijnen, Jos H.
    Schinkel, Alfred H.
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [25] De Novo Rational design of peptide-based covalent inhibitors via mapping of complementary binding site residues – technical protocol and case study on KRASG12C and BTK481C
    Ernest Oduro-Kwateng
    Musab Ali
    Ibrahim Oluwatobi Kehinde
    Li Rao
    Mahmoud E. S. Soliman
    BMC Methods, 2 (1):